Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.

Journal:

Journal of Clinical Oncology

Published:

2026-04-22

DOI:

10.1200/jco-25-02187

Affiliations:

40

Authors:

46

Go to article

Institutions	Authors	Share
Johnson & Johnson, United States of America (USA)	13.000000 13.000000	0.28
Yonsei Cancer Hospital, South Korea	1.500000	0.03
Asklepios Klinik Altona, Germany	1.000000	0.02
START-Madrid-FJD, Spain	1.000000	0.02
NYU Langone Health, United States of America (USA)	1.000000	0.02
National Taiwan University Hospital (NTUH), Taiwan	1.000000	0.02
UCLA Jonsson Comprehensive Cancer Center, United States of America (USA)	1.000000	0.02
START Midwest, United States of America (USA)	1.000000	0.02
Vanderbilt University Medical Center (VUMC), United States of America (USA)	1.000000	0.02
Princess Margaret Cancer Centre, U of T, Canada	1.000000	0.02
Beacon Hospital, Ireland	1.000000	0.02
Seoul St. Mary's Hospital, South Korea	1.000000	0.02
University Hospital of Munich (KUM), LMU, Germany	1.000000	0.02
Vall d'Hebron University Hospital (HUVH), ICS, Spain	1.000000	0.02
National Cheng Kung University Hospital, Taiwan	1.000000	0.02
Samsung Medical Center (SMC), South Korea	1.000000	0.02
The University of Texas MD Anderson Cancer Center, United States of America (USA)	1.000000	0.02
University of Malaya (UM), Malaysia	1.000000	0.02
Changhua Christian Hospital, Taiwan	1.000000	0.02
Antwerp University Hospital (UZA), UA, Belgium	1.000000	0.02
Seoul National University Hospital (SNUH), South Korea	1.000000	0.02
Kaohsiung Chang Gung Memorial Hospital, Chang Gung Medical Foundation, Taiwan	1.000000	0.02
Catholic University of Leuven (KU Leuven), Belgium	1.000000	0.02
Hospital Clínico Universitario de Valencia, Spain	1.000000	0.02
Ad‑Vance Medical Research, United States of America (USA)	1.000000	0.02
The Second Affiliated Hospital, Zhejiang University School of Medicine, China	1.000000	0.02
Asan Medical Center (AMC), South Korea	1.000000	0.02
IRCCS National Cancer Institute (INT) Milan, Italy	1.000000	0.02
University Hospitals Leuven (UZ Leuven), Belgium	1.000000	0.02
Johnson & Johnson Medical (China) Ltd., China	1.000000	0.02
Instituto de Investigación Marqués de Valdecilla (IDIVAL), HUMV, Spain	1.000000	0.02
Centro Comprensivo de Cáncer, UPR, United States of America (USA)	0.500000	0.01
Pan American Center for Oncology Trials (PanOncology), United States of America (USA)	0.500000	0.01
Severance Hospital, Yonsei University, South Korea	0.500000	0.01
Linkou Chang Gung Memorial Hospital, Chang Gung Medical Foundation, Taiwan	0.333333	0.01
Chang Gung University (CGU), Taiwan	0.333333	0.01
Chung Hua University (CHU), Taiwan	0.333333	0.01

Interested in Oncology and Carcinogenesis?